Your browser doesn't support javascript.
loading
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
Mateos, Maria-Victoria; Blacklock, Hilary; Schjesvold, Fredrik; Oriol, Albert; Simpson, David; George, Anupkumar; Goldschmidt, Hartmut; Larocca, Alessandra; Chanan-Khan, Asher; Sherbenou, Daniel; Avivi, Irit; Benyamini, Noam; Iida, Shinsuke; Matsumoto, Morio; Suzuki, Kenshi; Ribrag, Vincent; Usmani, Saad Z; Jagannath, Sundar; Ocio, Enrique M; Rodriguez-Otero, Paula; San Miguel, Jesus; Kher, Uma; Farooqui, Mohammed; Liao, Jason; Marinello, Patricia; Lonial, Sagar.
Afiliación
  • Mateos MV; Complejo Asistencial Universitario de Salamanca/IBSAL, Salamanca, Spain. Electronic address: mvmateos@usal.es.
  • Blacklock H; Middlemore Hospital, Auckland, New Zealand.
  • Schjesvold F; Oslo Myeloma Center, Oslo University Hospital and KG Jebsen Center for B-Cell Malignancies, University of Oslo, Oslo, Norway.
  • Oriol A; Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Triasi Pujol, Barcelona, Spain.
  • Simpson D; North Shore Hospital, Auckland, New Zealand.
  • George A; Wellington Blood and Cancer Center, Wellington, New Zealand.
  • Goldschmidt H; University Hospital Heidelberg and National Center of Tumor Diseases in Heidelberg, Heidelberg, Germany.
  • Larocca A; Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
  • Chanan-Khan A; Mayo Clinic, Jacksonville, FL, USA.
  • Sherbenou D; University of Colorado Cancer Center, Denver, CO, USA.
  • Avivi I; Sourasky Medical Center, Haifa, Israel.
  • Benyamini N; Rambam Health Care Campus, HaAliya HaShniya, Israel.
  • Iida S; Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Japan.
  • Matsumoto M; National Hospital Organization, Shibukawa Medical Center, Shibukawa, Gunma, Japan.
  • Suzuki K; Japanese Red Cross, Tokyo, Japan.
  • Ribrag V; Institut Gustave Roussy, Villejuif, France.
  • Usmani SZ; Levine Cancer Institute/Atrium Health, Charlotte, NC, USA.
  • Jagannath S; The Mount Sinai Medical Hospital, New York, NY, USA.
  • Ocio EM; Hospital Universitario Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain.
  • Rodriguez-Otero P; Clinica Universidad de Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain.
  • San Miguel J; Clinica Universidad de Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain.
  • Kher U; Merck & Co, Kenilworth, NJ, USA.
  • Farooqui M; Merck & Co, Kenilworth, NJ, USA.
  • Liao J; Merck & Co, Kenilworth, NJ, USA.
  • Marinello P; Merck & Co, Kenilworth, NJ, USA.
  • Lonial S; Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Lancet Haematol ; 6(9): e459-e469, 2019 Sep.
Article en En | MEDLINE | ID: mdl-31327687
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Talidomida / Dexametasona / Protocolos de Quimioterapia Combinada Antineoplásica / Anticuerpos Monoclonales Humanizados / Mieloma Múltiple Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies Límite: Aged / Aged80 / Female / Humans / Male Idioma: En Revista: Lancet Haematol Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Talidomida / Dexametasona / Protocolos de Quimioterapia Combinada Antineoplásica / Anticuerpos Monoclonales Humanizados / Mieloma Múltiple Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies Límite: Aged / Aged80 / Female / Humans / Male Idioma: En Revista: Lancet Haematol Año: 2019 Tipo del documento: Article